Kestra Medical Technologies reported a Q1 loss of $0.75 per share, missing EPS expectations of $0.61 by 22.95%, though it exceeded revenue estimates with $30.97 million (6.66% above consensus). The company has underperformed the S&P 500 by 25.7% year-to-date and carries a Zacks Rank #3 (Hold) rating, with mixed estimate revisions ahead.

Kestra Medical Technologies announced the appointment of Daniel Finney as Vice President of Research & Development and executive leadership team member. Finney, who has over 20 years of medical device development experience, succeeds Phillip D. Foshee, Jr. and will lead the company's innovation initiatives across the Cardiac Recovery System platform, including AI applications and strategic partnerships.

Phreesia reported Q3 2026 earnings of $0.03 per share, missing consensus estimates of $0.11 by 72.73%, though revenues slightly missed expectations at $129.46M. The stock has underperformed the S&P 500 by 41.5% year-to-date. With a Zacks Rank #3 (Hold) rating and mixed estimate revisions, the stock is expected to perform in line with the market near-term.

Kestra Medical Technologies announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience in a newly created role. Kopf, who previously led global customer experience at Insulet Corporation and served as Chief Experience Officer at REI, will oversee the patient experience for the ASSURE WCD device. The appointment aligns with Kestra's investments in commercial capabilities and artificial intelligence initiatives to drive growth and improve patient support throughout their cardiac recovery journey.

Kestra Medical Technologies (Nasdaq: KMTS), a wearable medical device and digital healthcare company, has been named a finalist in the 'Deal of the Year' category for the 2026 GeekWire Awards. The recognition is for the company's successful 2025 initial public offering, which the company states strengthens its ability to invest in growth and accelerate progress toward new standards of care for cardiac patients. Community voting is open through April 16, 2026, with winners to be announced on May 7, 2026.

Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company focuses on transforming patient outcomes in cardiovascular disease through monitoring and therapeutic intervention technologies.

Kestra Medical Technologies will report its second quarter fiscal 2026 financial results on December 11, with a conference call scheduled at 4:30 p.m. Eastern Time. The call will be available via webcast on their investor relations website.

Kestra Medical Technologies is conducting a public offering of 6,000,000 common shares at $23.00 per share, expecting to raise $138 million. The offering includes an option for underwriters to purchase an additional 900,000 shares.

Kestra Medical Technologies plans to offer 5,500,000 common shares through an underwritten public offering, with potential for an additional 825,000 shares. The proceeds will support sales, marketing, research, development, and general corporate purposes.

Kestra Medical Technologies reported a 52% revenue increase in Q1 FY2026, driven by rising ASSURE wearable defibrillator prescriptions. Despite strong top-line growth, the company experienced widening losses and increased operating expenses.

Kestra Medical Technologies, Ltd. (KMTS) announced the closing of its upsized initial public offering, raising approximately $202 million. The company's shares began trading on the Nasdaq Global Select Market.